Amgen Inc. (NASDAQ: AMGN) Stock Competitors & Peer Comparison
See AMGN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for AMGN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AMGN | $460.42 | +0.03% | 248.8B | 20.57 | $22.37 | +2.16% |
| LLY | $1,354.00 | -0.79% | 1.3T | 43.57 | $31.49 | +0.49% |
| JNJ | $276.22 | +1.43% | 664.8B | 25.74 | $10.73 | +1.92% |
| ABBV | $291.31 | +1.07% | 514.9B | 28.59 | $10.19 | +2.39% |
| MRK | $146.73 | -0.14% | 362B | 45.70 | $3.21 | +2.32% |
| NVS | $162.55 | +0.38% | 307B | 18.71 | $8.69 | +2.93% |
| AZN | $186.43 | -0.22% | 289.1B | 20.13 | $9.26 | +1.74% |
| GILD | $166.89 | -0.41% | 206.9B | -427.74 | -$0.39 | +1.94% |
| NVO | $40.31 | +0.02% | 177.7B | 10.03 | $4.02 | +4.46% |
| PFE | $29.39 | -0.20% | 167.5B | 9.63 | $3.05 | +5.87% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
AMGN vs LLY Comparison November 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 248.8B. In comparison, LLY has a market cap of 1.3T. Regarding current trading prices, AMGN is priced at $460.42 on the NASDAQ, while LLY trades at $1,354.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 20.57, whereas LLY's P/E ratio is 43.57. In terms of profitability, AMGN's ROE is +0.86%, compared to LLY's ROE of +0.84%. Regarding short-term risk, AMGN is more volatile compared to LLY. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
AMGN vs JNJ Comparison November 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 248.8B. In comparison, JNJ has a market cap of 664.8B. Regarding current trading prices, AMGN is priced at $460.42 on the NASDAQ, while JNJ trades at $276.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 20.57, whereas JNJ's P/E ratio is 25.74. In terms of profitability, AMGN's ROE is +0.86%, compared to JNJ's ROE of +0.20%. Regarding short-term risk, AMGN is less volatile compared to JNJ. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
AMGN vs ABBV Comparison November 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 248.8B. In comparison, ABBV has a market cap of 514.9B. Regarding current trading prices, AMGN is priced at $460.42 on the NASDAQ, while ABBV trades at $291.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 20.57, whereas ABBV's P/E ratio is 28.59. In terms of profitability, AMGN's ROE is +0.86%, compared to ABBV's ROE of -2.03%. Regarding short-term risk, AMGN is less volatile compared to ABBV. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
AMGN vs MRK Comparison November 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 248.8B. In comparison, MRK has a market cap of 362B. Regarding current trading prices, AMGN is priced at $460.42 on the NASDAQ, while MRK trades at $146.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 20.57, whereas MRK's P/E ratio is 45.70. In terms of profitability, AMGN's ROE is +0.86%, compared to MRK's ROE of +0.05%. Regarding short-term risk, AMGN is more volatile compared to MRK. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check MRK's competition here
Novartis AG (NYSE: NVS)
AMGN vs NVS Comparison November 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 248.8B. In comparison, NVS has a market cap of 307B. Regarding current trading prices, AMGN is priced at $460.42 on the NASDAQ, while NVS trades at $162.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 20.57, whereas NVS's P/E ratio is 18.71. In terms of profitability, AMGN's ROE is +0.86%, compared to NVS's ROE of +0.25%. Regarding short-term risk, AMGN is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
AMGN vs AZN Comparison November 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 248.8B. In comparison, AZN has a market cap of 289.1B. Regarding current trading prices, AMGN is priced at $460.42 on the NASDAQ, while AZN trades at $186.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 20.57, whereas AZN's P/E ratio is 20.13. In terms of profitability, AMGN's ROE is +0.86%, compared to AZN's ROE of +0.22%. Regarding short-term risk, AMGN is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check AZN's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
AMGN vs GILD Comparison November 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 248.8B. In comparison, GILD has a market cap of 206.9B. Regarding current trading prices, AMGN is priced at $460.42 on the NASDAQ, while GILD trades at $166.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 20.57, whereas GILD's P/E ratio is -427.74. In terms of profitability, AMGN's ROE is +0.86%, compared to GILD's ROE of -0.22%. Regarding short-term risk, AMGN is more volatile compared to GILD. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check GILD's competition here
Novo Nordisk A/S (NYSE: NVO)
AMGN vs NVO Comparison November 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 248.8B. In comparison, NVO has a market cap of 177.7B. Regarding current trading prices, AMGN is priced at $460.42 on the NASDAQ, while NVO trades at $40.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 20.57, whereas NVO's P/E ratio is 10.03. In terms of profitability, AMGN's ROE is +0.86%, compared to NVO's ROE of +0.54%. Regarding short-term risk, AMGN is more volatile compared to NVO. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check NVO's competition here
Pfizer Inc. (NYSE: PFE)
AMGN vs PFE Comparison November 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 248.8B. In comparison, PFE has a market cap of 167.5B. Regarding current trading prices, AMGN is priced at $460.42 on the NASDAQ, while PFE trades at $29.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 20.57, whereas PFE's P/E ratio is 9.63. In terms of profitability, AMGN's ROE is +0.86%, compared to PFE's ROE of +0.05%. Regarding short-term risk, AMGN is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
AMGN vs BMY Comparison November 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 248.8B. In comparison, BMY has a market cap of 127.1B. Regarding current trading prices, AMGN is priced at $460.42 on the NASDAQ, while BMY trades at $62.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 20.57, whereas BMY's P/E ratio is 10.48. In terms of profitability, AMGN's ROE is +0.86%, compared to BMY's ROE of +0.44%. Regarding short-term risk, AMGN is more volatile compared to BMY. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check BMY's competition here
Sanofi (NASDAQ: SNY)
AMGN vs SNY Comparison November 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 248.8B. In comparison, SNY has a market cap of 113.7B. Regarding current trading prices, AMGN is priced at $460.42 on the NASDAQ, while SNY trades at $47.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 20.57, whereas SNY's P/E ratio is 10.24. In terms of profitability, AMGN's ROE is +0.86%, compared to SNY's ROE of +0.06%. Regarding short-term risk, AMGN is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check SNY's competition here
GSK plc (NYSE: GSK)
AMGN vs GSK Comparison November 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 248.8B. In comparison, GSK has a market cap of 101.8B. Regarding current trading prices, AMGN is priced at $460.42 on the NASDAQ, while GSK trades at $50.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 20.57, whereas GSK's P/E ratio is 10.87. In terms of profitability, AMGN's ROE is +0.86%, compared to GSK's ROE of +0.23%. Regarding short-term risk, AMGN is less volatile compared to GSK. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check GSK's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
AMGN vs CELG-RI Comparison November 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 248.8B. In comparison, CELG-RI has a market cap of 94.8B. Regarding current trading prices, AMGN is priced at $460.42 on the NASDAQ, while CELG-RI trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 20.57, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, AMGN's ROE is +0.86%, compared to CELG-RI's ROE of +0.44%. Regarding short-term risk, AMGN is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check CELG-RI's competition here
Biogen Inc. (NASDAQ: BIIB)
AMGN vs BIIB Comparison November 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 248.8B. In comparison, BIIB has a market cap of 36.7B. Regarding current trading prices, AMGN is priced at $460.42 on the NASDAQ, while BIIB trades at $248.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 20.57, whereas BIIB's P/E ratio is 15.69. In terms of profitability, AMGN's ROE is +0.86%, compared to BIIB's ROE of +0.02%. Regarding short-term risk, AMGN is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check BIIB's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
AMGN vs HZNP Comparison November 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 248.8B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, AMGN is priced at $460.42 on the NASDAQ, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 20.57, whereas HZNP's P/E ratio is 61.86. In terms of profitability, AMGN's ROE is +0.86%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, AMGN is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
AMGN vs GRFS Comparison November 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 248.8B. In comparison, GRFS has a market cap of 7.1B. Regarding current trading prices, AMGN is priced at $460.42 on the NASDAQ, while GRFS trades at $8.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 20.57, whereas GRFS's P/E ratio is 9.69. In terms of profitability, AMGN's ROE is +0.86%, compared to GRFS's ROE of +0.09%. Regarding short-term risk, AMGN is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
AMGN vs OGN Comparison November 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 248.8B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, AMGN is priced at $460.42 on the NASDAQ, while OGN trades at $13.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 20.57, whereas OGN's P/E ratio is 4.13. In terms of profitability, AMGN's ROE is +0.86%, compared to OGN's ROE of +0.22%. Regarding short-term risk, AMGN is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check OGN's competition here
Amarin Corporation plc (NASDAQ: AMRN)
AMGN vs AMRN Comparison November 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 248.8B. In comparison, AMRN has a market cap of 241.1M. Regarding current trading prices, AMGN is priced at $460.42 on the NASDAQ, while AMRN trades at $11.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 20.57, whereas AMRN's P/E ratio is -116.55. In terms of profitability, AMGN's ROE is +0.86%, compared to AMRN's ROE of -0.04%. Regarding short-term risk, AMGN is less volatile compared to AMRN. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check AMRN's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
AMGN vs MIRA Comparison November 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 248.8B. In comparison, MIRA has a market cap of 23.3M. Regarding current trading prices, AMGN is priced at $460.42 on the NASDAQ, while MIRA trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 20.57, whereas MIRA's P/E ratio is -0.38. In terms of profitability, AMGN's ROE is +0.86%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, AMGN is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check MIRA's competition here
Scilex Holding Company (NASDAQ: SCLX)
AMGN vs SCLX Comparison November 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 248.8B. In comparison, SCLX has a market cap of 11.7M. Regarding current trading prices, AMGN is priced at $460.42 on the NASDAQ, while SCLX trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 20.57, whereas SCLX's P/E ratio is -0.04. In terms of profitability, AMGN's ROE is +0.86%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, AMGN is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check SCLX's competition here
Scilex Holding Company (NASDAQ: SCLXW)
AMGN vs SCLXW Comparison November 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 248.8B. In comparison, SCLXW has a market cap of 7.6M. Regarding current trading prices, AMGN is priced at $460.42 on the NASDAQ, while SCLXW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 20.57, whereas SCLXW's P/E ratio is N/A. In terms of profitability, AMGN's ROE is +0.86%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, AMGN is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check SCLXW's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
AMGN vs BDSIW Comparison November 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 248.8B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, AMGN is priced at $460.42 on the NASDAQ, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 20.57, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, AMGN's ROE is +0.86%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, AMGN is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
AMGN vs CRXT Comparison November 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 248.8B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, AMGN is priced at $460.42 on the NASDAQ, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 20.57, whereas CRXT's P/E ratio is -0.02. In terms of profitability, AMGN's ROE is +0.86%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, AMGN is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check CRXT's competition here